Samfara Acquires Chr. Olesen Synthesis, a Danish API Manufacturer Specializing in Controlled Substances
Samfara, a European life sciences investment firm based in London, has completed the acquisition of Chr. Olesen Synthesis from its previous owner and Signet Healthcare Partners. The company specializes in manufacturing active pharmaceutical ingredients (APIs) for controlled substances used to treat conditions like opioid use disorder and ADHD. Located near Copenhagen with cGMP-certified production since 2015, it serves clients across Europe, North America, and the Middle East. With Samfara's backing, Chr. Olesen Synthesis aims to expand its capabilities, strengthen customer relationships, and enter new markets both organically and through acquisitions. Jean-François Hilaire, former CEO of Unither and EVP at Recipharm, will join as board chair. The transaction was supported by a syndicate of European and North American institutional investors. The acquisition aligns with Samfara's strategy to invest in complex niche businesses within the life sciences sector that can benefit from active ownership and strategic support.
Topics: Active Pharmaceutical Ingredients (API) Life Sciences Investment Pharmaceuticals